Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$1.77 - $3.09 $80,021 - $139,698
-45,210 Reduced 23.6%
146,326 $276,000
Q3 2023

Nov 14, 2023

BUY
$2.23 - $4.69 $100,818 - $212,034
45,210 Added 30.9%
191,536 $440,000
Q2 2023

Aug 14, 2023

BUY
$3.11 - $4.91 $455,073 - $718,460
146,326 New
146,326 $534,000
Q2 2022

Aug 15, 2022

SELL
$2.49 - $5.92 $292,144 - $694,575
-117,327 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$4.41 - $12.28 $149,966 - $417,593
34,006 Added 40.81%
117,327 $659,000
Q4 2021

Feb 14, 2022

SELL
$10.86 - $17.85 $121,870 - $200,312
-11,222 Reduced 11.87%
83,321 $868,000
Q3 2021

Nov 12, 2021

SELL
$10.06 - $15.3 $17,122 - $26,040
-1,702 Reduced 1.77%
94,543 $1.22 Million
Q2 2021

Aug 16, 2021

SELL
$10.9 - $14.53 $70,021 - $93,340
-6,424 Reduced 6.26%
96,245 $1.12 Million
Q1 2021

May 17, 2021

SELL
$11.2 - $16.09 $444,550 - $638,644
-39,692 Reduced 27.88%
102,669 $1.25 Million
Q4 2020

Feb 16, 2021

BUY
$11.12 - $16.4 $10,130 - $14,940
911 Added 0.64%
142,361 $1.78 Million
Q3 2020

Nov 16, 2020

SELL
$15.05 - $23.54 $50,989 - $79,753
-3,388 Reduced 2.34%
141,450 $2.13 Million
Q2 2020

Aug 14, 2020

BUY
$12.7 - $30.73 $740,143 - $1.79 Million
58,279 Added 67.33%
144,838 $3.55 Million
Q1 2020

May 14, 2020

SELL
$9.85 - $22.27 $435,567 - $984,779
-44,220 Reduced 33.81%
86,559 $0
Q4 2019

Feb 14, 2020

BUY
$7.06 - $17.47 $429,424 - $1.06 Million
60,825 Added 86.95%
130,779 $2.08 Million
Q3 2019

Nov 14, 2019

BUY
$6.78 - $9.28 $44,781 - $61,294
6,605 Added 10.43%
69,954 $590,000
Q2 2019

Aug 15, 2019

BUY
$7.18 - $9.65 $454,845 - $611,317
63,349 New
63,349 $570,000

Others Institutions Holding CUE

About Cue Biopharma, Inc.


  • Ticker CUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,381,700
  • Market Cap $24.1M
  • Description
  • Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...
More about CUE
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.